Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dimerization: a versatile switch for oncogenesis.

Chi Wai So1, Michael L Cleary

  • 1Department of Pathology, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, CA 94305, USA. ericso@stanford.edu

Blood
|May 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-function relationship of ASH1L and histone H3K36 and H3K4 methylation.

Nature communications·2025
Same author

Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic leukemia.

Blood·2024
Same author

Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.

Blood advances·2024
Same author

Author Correction: Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants.

Nature medicine·2023
Same author

Genome editing-induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion.

The Journal of clinical investigation·2023
Same author

Age and ligand specificity influence the outcome of pathogen engagement on preleukemic and leukemic B-cell precursor populations.

Blood advances·2023
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
Same journal

Precision Transfusion Medicine in the Omics Era.

Blood·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
See all related articles

Chimeric transcription factors drive acute leukemias through forced dimerization, altering gene expression. Targeting cofactor recruitment or dimerization offers promising therapeutic strategies for leukemia.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Chimeric transcription factors, resulting from chromosomal rearrangements, are implicated in acute leukemias.
  • Forced dimerization or oligomerization of these factors is a key mechanism driving oncogenesis.

Purpose of the Study:

  • To elucidate the mechanisms by which forced dimerization of chimeric transcription factors contributes to leukemogenesis.
  • To investigate the role of recruited transcriptional cofactors in the aberrant gene expression associated with chimeric oncoproteins.

Main Methods:

  • Analysis of chimeric transcription factor structure and function.
  • Investigation of protein-protein interactions and cofactor recruitment.
  • Assessment of effects on target gene expression and leukemogenesis.

Related Experiment Videos

Main Results:

  • Forced dimerization alters DNA-binding protein associations and cofactor recruitment.
  • Recruitment of coactivators or corepressors by dimerized oncoproteins leads to aberrant gene expression.
  • Specific examples include RARalpha and AML1 (acute myeloid leukemia 1) chimeras recruiting corepressors, and MLL (mixed-lineage leukemia) chimeras recruiting coactivators.

Conclusions:

  • Forced dimerization of chimeric transcription factors is a critical oncogenic mechanism in acute leukemias.
  • The nature of recruited cofactors dictates the transcriptional outcome (repression or activation).
  • Targeting cofactor enzymatic activities or dimerization interfaces presents potential therapeutic strategies.